Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 385

1.

How to avoid the inappropriate use of antibiotics in upper respiratory tract infections? A position statement from an expert panel.

Piltcher OB, Kosugi EM, Sakano E, Mion O, Testa JRG, Romano FR, Santos MCJ, Di Francesco RC, Mitre EI, Bezerra TFP, Roithmann R, Padua FG, Valera FCP, Lubianca Neto JF, Sá LCB, Pignatari SSN, Avelino MAG, Caixeta JAS, Anselmo-Lima WT, Tamashiro E.

Braz J Otorhinolaryngol. 2018 Feb 25. pii: S1808-8694(18)30026-0. doi: 10.1016/j.bjorl.2018.02.001. [Epub ahead of print]

2.

The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma.

Mehrazin R, Dulaimi E, Uzzo RG, Devarjan K, Pei J, Smaldone MC, Kutikov A, Testa JR, Al-Saleem T.

Ther Adv Urol. 2017 Oct 31;10(1):3-10. doi: 10.1177/1756287217732660. eCollection 2018 Jan.

3.

Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains.

Peng H, Prokop J, Karar J, Park K, Cao L, Harbour JW, Bowcock AM, Malkowicz SB, Cheung M, Testa JR, Rauscher FJ.

Cancer Res. 2017 Dec 28. pii: canres.2876.2017. doi: 10.1158/0008-5472.CAN-17-2876. [Epub ahead of print]

PMID:
29284740
4.

Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

Tan Y, Sementino E, Chernoff J, Testa JR.

Am J Cancer Res. 2017 Aug 1;7(8):1724-1737. eCollection 2017.

5.

BAP1, a tumor suppressor gene driving malignant mesothelioma.

Cheung M, Testa JR.

Transl Lung Cancer Res. 2017 Jun;6(3):270-278. doi: 10.21037/tlcr.2017.05.03. Review.

6.

Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma.

Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, O'Neill R, Solomides C, Peiper SC, Testa JR, Uzzo R, Yang H.

Oncotarget. 2017 Jun 6;8(23):37423-37434. doi: 10.18632/oncotarget.16965.

7.

The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.

Tan Y, Sementino E, Xu J, Pei J, Liu Z, Ito TK, Cai KQ, Peri S, Klein-Szanto AJ, Wiest DL, Testa JR.

Oncotarget. 2017 Feb 28;8(9):14941-14956. doi: 10.18632/oncotarget.14784.

8.

Identification of Akt interaction protein PHF20/TZP that transcriptionally regulates p53.

Park S, Kim D, Dan HC, Chen H, Testa JR, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22852. No abstract available.

9.

ArgBP2γ interacts with Akt and p21-activated kinase-1 and promotes cell survival.

Yuan ZQ, Kim D, Kaneko S, Sussman M, Bokoch GM, Kruh GD, Nicosia SV, Testa JR, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22845. No abstract available.

10.

Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma.

Jiang W, Dulaimi E, Devarajan K, Parsons T, Wang Q, Liao L, Cho EA, O'Neill R, Solomides C, Peiper SC, Testa JR, Uzzo R, Yang H.

PLoS One. 2016 Oct 20;11(10):e0164554. doi: 10.1371/journal.pone.0164554. eCollection 2016.

11.

Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation.

Peri S, Caretti E, Tricarico R, Devarajan K, Cheung M, Sementino E, Menges CW, Nicolas E, Vanderveer LA, Howard S, Conrad P, Crowell JA, Campbell KS, Ross EA, Godwin AK, Yeung AT, Clapper ML, Uzzo RG, Henske EP, Ricketts CJ, Vocke CD, Linehan WM, Testa JR, Bellacosa A, Kopelovich L, Knudson AG.

Oncotarget. 2017 Mar 14;8(11):17628-17642. doi: 10.18632/oncotarget.12192.

12.

Genomic imbalances in peripheral blood confirm the diagnosis of myelodysplastic syndrome in a patient presenting with non-immune hemolytic anemia.

Zahid MF, Khan N, Pei J, Testa JR, Dulaimi E.

Leuk Res Rep. 2016 May 13;5:23-6. doi: 10.1016/j.lrr.2016.05.001. eCollection 2016.

13.

Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.

Rao S, Cai KQ, Stadanlick JE, Greenberg-Kushnir N, Solanki-Patel N, Lee SY, Fahl SP, Testa JR, Wiest DL.

Cancer Res. 2016 Jun 1;76(11):3387-96. doi: 10.1158/0008-5472.CAN-15-2698. Epub 2016 Apr 5.

14.

Inflammation-Related IL1β/IL1R Signaling Promotes the Development of Asbestos-Induced Malignant Mesothelioma.

Kadariya Y, Menges CW, Talarchek J, Cai KQ, Klein-Szanto AJ, Pietrofesa RA, Christofidou-Solomidou M, Cheung M, Mossman BT, Shukla A, Testa JR.

Cancer Prev Res (Phila). 2016 May;9(5):406-414. doi: 10.1158/1940-6207.CAPR-15-0347. Epub 2016 Mar 2.

15.

Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.

Kadariya Y, Cheung M, Xu J, Pei J, Sementino E, Menges CW, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Testa JR.

Cancer Res. 2016 May 1;76(9):2836-44. doi: 10.1158/0008-5472.CAN-15-3371. Epub 2016 Feb 19.

16.

Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.

Borczuk AC, Pei J, Taub RN, Levy B, Nahum O, Chen J, Chen K, Testa JR.

Cancer Biol Ther. 2016;17(3):328-35. doi: 10.1080/15384047.2016.1145850. Epub 2016 Feb 6.

17.

Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.

Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR.

Cancer Res. 2016 Jan 15;76(2):206-15. doi: 10.1158/0008-5472.CAN-15-0295. Epub 2015 Dec 30. Erratum in: Cancer Res. 2017 Jun 1;77(11):3124. Cancer Res. 2018 Jan 1;78(1):309.

18.

Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice.

Pietrofesa RA, Velalopoulou A, Arguiri E, Menges CW, Testa JR, Hwang WT, Albelda SM, Christofidou-Solomidou M.

Carcinogenesis. 2016 Feb;37(2):177-87. doi: 10.1093/carcin/bgv174. Epub 2015 Dec 17.

19.

Transcanal endoscopic myringoplasty: a case series in a university center.

Garcia Lde B, Moussalem GF, Andrade JS, Mangussi-Gomes J, Cruz OL, Penido Nde O, Testa JR.

Braz J Otorhinolaryngol. 2016 May-Jun;82(3):321-5. doi: 10.1016/j.bjorl.2015.05.012. Epub 2015 Nov 6.

20.

Genomic Copy Number Alterations in Renal Cell Carcinoma with Sarcomatoid Features.

Ito T, Pei J, Dulaimi E, Menges C, Abbosh PH, Smaldone MC, Chen DY, Greenberg RE, Kutikov A, Viterbo R, Uzzo RG, Testa JR.

J Urol. 2016 Apr;195(4 Pt 1):852-8. doi: 10.1016/j.juro.2015.10.180. Epub 2015 Nov 18.

21.

Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts.

Tan Y, Xin X, Coffey FJ, Wiest DL, Dong LQ, Testa JR.

J Cell Physiol. 2016 May;231(5):1142-50. doi: 10.1002/jcp.25211. Epub 2015 Oct 21.

22.

Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.

Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, Testa JR.

Cancer Lett. 2015 Dec 28;369(2):261-5. doi: 10.1016/j.canlet.2015.09.011. Epub 2015 Sep 26.

23.

An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.

Cheung M, Kadariya Y, Pei J, Talarchek J, Facciolo F, Visca P, Righi L, Cozzi I, Testa JR, Ascoli V.

Cancer Genet. 2015 Oct;208(10):502-7. doi: 10.1016/j.cancergen.2015.07.004. Epub 2015 Jul 30.

24.

Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas.

Lee HO, He X, Mookerjee-Basu J, Zhongping D, Hua X, Nicolas E, Sulis ML, Ferrando AA, Testa JR, Kappes DJ.

Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7773-8. doi: 10.1073/pnas.1424104112. Epub 2015 Jun 8.

25.

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.

Kalra N, Zhang J, Thomas A, Xi L, Cheung M, Talarchek J, Burkett S, Tsokos MG, Chen Y, Raffeld M, Miettinen M, Pastan I, Testa JR, Hassan R.

BMC Cancer. 2015 May 8;15:376. doi: 10.1186/s12885-015-1362-2.

26.

The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.

Liao L, Testa JR, Yang H.

Cancer Genet. 2015 May;208(5):206-14. doi: 10.1016/j.cancergen.2015.02.008. Epub 2015 Feb 20. Review.

27.

Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.

Tan Y, Sementino E, Pei J, Kadariya Y, Ito TK, Testa JR.

Cancer Biol Ther. 2015;16(4):580-8. doi: 10.1080/15384047.2015.1018495. Epub 2015 Mar 20.

28.

Expression of aquaporin 2 following facial nerve crush in rats.

Neiva FC, Borin A, Lee KS, Dias MV, Rodrigues BR, Testa JR, Cruz OL, Covolan L.

Acta Otolaryngol. 2015 Jul;135(7):741-5. doi: 10.3109/00016489.2015.1010104. Epub 2015 Mar 11.

PMID:
25762220
29.

Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.

Albury TM, Pandey V, Gitto SB, Dominguez L, Spinel LP, Talarchek J, Klein-Szanto AJ, Testa JR, Altomare DA.

Neoplasia. 2015 Feb;17(2):175-82. doi: 10.1016/j.neo.2014.12.006.

30.

SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR.

J Thorac Oncol. 2015 Feb;10(2):387-91. doi: 10.1097/JTO.0000000000000360.

31.

Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.

Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T.

Mol Cancer Res. 2015 Apr;13(4):795-806. doi: 10.1158/1541-7786.MCR-14-0314. Epub 2014 Dec 17.

32.

Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy.

Deng XB, Xiao L, Wu Y, Jin F, Mossman B, Testa JR, Xiao GH.

Int J Cancer. 2015 Jul 15;137(2):481-90. doi: 10.1002/ijc.29391. Epub 2014 Dec 27.

33.

Anatomical study of the pigs temporal bone by microdissection.

Garcia Lde B, Andrade JS, Testa JR.

Acta Cir Bras. 2014;29 Suppl 3:77-80.

34.

Anatomical study of the pigs temporal bone by microdissection.

Garcia Lde B, Andrade JS, Testa JR.

Acta Cir Bras. 2014;29 Suppl 1:69-72.

35.

Tissue response evaluation of the mucosa of the tympanic cavity of guinea pigs, when receiving biodegradable implant.

Garcia Lde B, Cunha Junior Ada S, Fialho SL, Perez AC, Barros BB, Dorigueto RS, Testa JR.

Acta Cir Bras. 2014;29 Suppl 1:12-8.

36.

Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.

Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, Karar J, Rauscher FJ, Testa JR.

Cancer Res. 2014 Aug 15;74(16):4388-97. doi: 10.1158/0008-5472.CAN-14-1328. Epub 2014 Jun 13.

37.

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA.

Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639.

38.

In memoriam: Janet D. Rowley, MD (April 5, 1925-December 17, 2013).

Zeleznik-Le NJ, Testa JR.

Cancer Genet. 2014 Jan-Feb;207(1-2):46-7. No abstract available.

PMID:
24795993
39.

Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pei J, Robu V, Feder M, Cheung M, Neumann-Domer E, Talarchek J, Dulaimi E, Millenson MM, Testa JR.

Cancer Genet. 2014 Mar;207(3):98-102. doi: 10.1016/j.cancergen.2014.02.005. Epub 2014 Feb 15.

40.

Molecular cytogenetic analysis of the scleractinian coral Acropora solitaryensis Veron & Wallace 1984.

Taguchi T, Mezaki T, Iwase F, Sekida S, Kubota S, Fukami H, Okuda K, Shinbo T, Oshima S, Iiguni Y, Testa JR, Tominaga A.

Zoolog Sci. 2014 Feb;31(2):89-94. doi: 10.2108/zsj.31.89.

PMID:
24521318
41.

Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.

Menges CW, Kadariya Y, Altomare D, Talarchek J, Neumann-Domer E, Wu Y, Xiao GH, Shapiro IM, Kolev VN, Pachter JA, Klein-Szanto AJ, Testa JR.

Cancer Res. 2014 Feb 15;74(4):1261-1271. doi: 10.1158/0008-5472.CAN-13-2062. Epub 2013 Dec 26.

42.

The impact of endoscopy on the treatment of cholesteatomas.

Lima Tde O, Araújo TF, Soares LC, Testa JR.

Braz J Otorhinolaryngol. 2013 Aug;79(4):505-11. doi: 10.5935/1808-8694.20130090. Review. English, Portuguese.

43.

[Experimental model of facial paralysis by nerve compression in primates (Callithrix sp.): A new model of facial paralysis in small nonhuman primates].

Neiva FC, Borin A, Cinini S, Mello LE, Cruz OL, Testa JR.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013 Apr;27(8):429-31. Chinese. No abstract available.

PMID:
23858728
44.

Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.

Cheung M, Talarchek J, Schindeler K, Saraiva E, Penney LS, Ludman M, Testa JR.

Cancer Genet. 2013 May;206(5):206-10. doi: 10.1016/j.cancergen.2013.05.018. Review.

PMID:
23849051
45.

Connecting molecular pathways to hereditary cancer risk syndromes.

Testa JR, Malkin D, Schiffman JD.

Am Soc Clin Oncol Educ Book. 2013:81-90. doi: 10.1200/EdBook_AM.2013.33.81. Review.

46.

NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma.

Thapa RJ, Chen P, Cheung M, Nogusa S, Pei J, Peri S, Testa JR, Balachandran S.

Mol Cancer Ther. 2013 Aug;12(8):1568-78. doi: 10.1158/1535-7163.MCT-12-1010. Epub 2013 May 8.

47.

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.

Hisamatsu T, Mabuchi S, Matsumoto Y, Kawano M, Sasano T, Takahashi R, Sawada K, Ito K, Kurachi H, Schilder RJ, Testa JR, Kimura T.

Mol Cancer Ther. 2013 Jul;12(7):1367-77. doi: 10.1158/1535-7163.MCT-12-1185. Epub 2013 Apr 24.

48.

BAP1 and cancer.

Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G.

Nat Rev Cancer. 2013 Mar;13(3):153-9. doi: 10.1038/nrc3459. Review.

49.

Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.

Ma L, Zhang G, Miao XB, Deng XB, Wu Y, Liu Y, Jin ZR, Li XQ, Liu QZ, Sun DX, Testa JR, Yao KT, Xiao GH.

FEBS J. 2013 May;280(9):2027-41. doi: 10.1111/febs.12226. Epub 2013 Apr 8.

50.

Diverse mechanisms of AKT pathway activation in human malignancy.

Cheung M, Testa JR.

Curr Cancer Drug Targets. 2013 Mar;13(3):234-44. Review.

Supplemental Content

Loading ...
Support Center